https://www.selleckchem.com/TGF-beta.html
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid cardiomyopathy (ATTR-CM). This study aimed to evaluate tolerability, clinical outcomes, and changes in NT-proBNP levels and glomerular filtration rate (GFR) in ATTR-CM patients treated with dapagliflozin. Patients with stable, tafamidis-treated ATTR-CM were retrospectively evaluated at the initiation of dapagliflozi
Like
Comment
Share
